News

GlaxoSmithKline has announced that it has entered into an agreement to form a new joint venture with Shenzhen Neptunus Interlong. The latter is focused on developing and manufacturing

Pharmasset has announced the completion of the single ascending dose study, and has begun dosing in a multiple ascending dose trial with PSI-7851. Its a nucleotide analog polymerase

“Today’s announcement marks another milestone in the successful partnership between ICON and Lilly,” commented Peter Gray, CEO at ICON. “We have worked together to create a truly flexible

DOR has announced that it has received Protocol Assistance feedback from the European Medicines Agency (EMEA) on the design of its confirmatory, pivotal, Phase-III clinical trial. The trial

Abbott has launched the EAS Myoplex Strength Formula nutrition shake, designed to help sportsmen and fitness seekers refuel after physical activity. The ready-to-drink sports nutrition shake comes in

BioLife Solutions has announced the completion of construction and validation of its internal GMP manufacturing facility. The company has released first production lot of its biopreservation media products

Halozyme, a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, has announced that Roche has selected a fifth exclusive target under the existing license and collaboration

Bioniche and Synerx have announced the FDA approval and launch of Melphalan Hydrochloride for Injection, the generic equivalent of Alkeran from GlaxoSmithKline. Bioniche and Synerx entered into an

United Therapeutics and Eli Lilly have announced the results of a pivotal 16-week study. The results showed that once-daily dose of tadalafil was generally well tolerated, improved exercise